São Paulo, December 2020 – Eurofarma, a pharmaceutical company with operations in 20 Latin American countries, is reinforcing its operations in Mexico by acquiring the antibiotic Keflex from the Eli Lilly laboratory. Cephalexin, the active ingredient of the product, is indicated for the treatment of respiratory tract infections (bacterial sinusitis and otitis), skin and soft tissue infections, infections of the bones and joints, genitourinary tract infections, including acute prostatitis, and dental infections.
Keflex has been sold in the Mexican market for 50 years and is one of the many products to be added to Eurofarma’s portfolio in the country starting in 2021. The brand is widely recalled and recognized by the medical class as the novel Cephalexin. Despite losing its patent, Keflex remains the most commonly prescribed antibiotic molecule in Mexico (Source: Close-up).
The antibiotic will be added to Takeda’s newly acquired portfolio, an important product line in Mexico with brands recognized by the medical class, including innovative and patented molecules.
This acquisition reaffirms not only Eurofarma’s goal of strengthening its strategy to enter the Mexican market – the second most relevant in Latin America –, but also its commitment to its internationalizationproject. The goal highlighted in Eurofarma’s 2022 Vision establishes that international operations will represent 30% of the company’s total sales.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.
EUROFARMA ON SOCIAL MEDIA
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarmalab | Twitter: @eurofarmaLab
Youtube: @eurofarmalab